Aura Biosciences, Inc. (AURA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-88.8%

$0.67

vs $6.03 price

Levered DCF

$0.70

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

8.97

Safe zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-3.1×	-4.7×	-4.59×	-5.36×	-10.75×	-14.37×	-1,783.13×
P/B	2.4×	2.69×	1.55×	1.61×	3.26×	22.33×	1,405.75×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-2.73×	-4.62×	-4.4×	-3.71×	-10.11×	-19.42×	-1,824.39×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	8.15×	10.77×	18.76×	18.81×	20.9×	6.94×	5.42×
Debt / equity	0.13×	0.12×	0.09×	0.11×	0.01×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	-7,402×	-4,828×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-77.6%	-57.2%	-33.8%	-30.0%	-23.1%	-114.7%	-78.7%
Return on invested capital	-73.1%	-56.3%	-34.6%	-27.9%	-23.0%	-114.1%	-78.1%
Return on assets	-62.7%	-47.6%	-30.0%	-26.2%	-22.0%	-100.5%	-65.3%
Free cash flow yield	-25.9%	-19.9%	-18.4%	-17.7%	-7.0%	-5.8%	-0.1%
Earnings yield	-32.3%	-21.3%	-21.8%	-18.7%	-7.1%	-5.1%	-0.1%
Enterprise value	$286.7M	$395.2M	$329.5M	$213.6M	$347.9M	$415.1M	$43.2B
Net debt / EBITDA	0.4×	0.15×	0.29×	1.75×	4.3×	0.81×	1.37×
Cash conversion cycle (days)	0	0	-504	0	0	0	-1,672